Other languages Sinopharm Group Co. Ltd.

Equities

1099

CNE100000FN7

Market Closed - Hong Kong S.E. Other stock markets 01:38:22 29/04/2024 pm IST			5-day change	1st Jan Change
20.2 ^HKD	-6.26%		-3.81%	-1.22%

10:46am	China, Hong Kong stocks rise, led by property shares	RE
05:47am	Sinopharm Group Shares Fall as Higher Costs Cut Into Quarterly Profit	DJ

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

China, Hong Kong stocks rise, led by property shares	02:16pm
Sinopharm Group's Q1 Profit Falls as Operating Costs Rise	08:09am
Central Bank, Tech Outlooks Lift Major Asian Stock Markets	26/04
Borse Cina : chiudono miste, in rialzo Hong Kong con decisione su tassi	22/04
Chinese FDA Grants Marketing Approval for Shyndec Subsidiary's Drug Raw Materials	10/04
China Production Bases of Shyndec Pharmaceutical's Unit Gets Compliance Certification from Australian Regulator	27/03
Sinopharm's Attributable Profit Jumps in 2023 on Higher Revenue	25/03
Sinopharm Group Co. Ltd. Proposes Final Dividend of for the Financial Year Ended 31 December 2023, Payable on 13 August 2024	25/03
Sinopharm Group Co. Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	25/03
China Stocks Muted at Close as Recovery Optimism Fades; Sinopharm Jumps 6% on Upbeat 2023 Earnings	21/03
Sinopharm's 2023 Profit Climbs 9%; Shares Up 6%	21/03
US Inflation, Light News Flow Churns Asian Stock Markets	13/03
China Traditional Chinese Medicine's Stock Bolts on Privatization Offer	22/02
China stocks extend gains led by coal, AI; HK shares up	22/02
Hong Kong Stocks Hover Near Two-Month Highs Amid Mixed Corporate Earnings	22/02
China stocks jump with AI shares leading on Nvidia forecast; HK shares flat	22/02
Sinopharm offers to take China-TCM private in nearly $3 bln deal	21/02
Shyndec Pharma Unit's Cefotaxime Sodium for Injection Passes Drug Regulator's Consistency Evaluation	21/02
Cancer Drug of Shyndec Pharma's Unit Passes Drug Regulator's Evaluation	20/02
Shyndec Pharma Unit Obtains Antihistamine Marketing Rights for 7.7 Million Yuan	03/01

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Sinopharm Group Co. Ltd.

Equities

1099

CNE100000FN7

Other languages

Filters